Physician profile
Mariam Mathai
NPI 1346694668
$4,204.15
in general payments reported to CMS, 2019-2025
21 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 76% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $59.58 · 2021: $463 · 2022: $728 · 2023: $885 · 2024: $680 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $618.38 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $483.47 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $466.16 | 2020-2024 | Precision 1, Dailies Total1, Total30 |
| Genentech USA, INC. | $413.55 | 2021-2025 | Susvimo, Vabysmo |
| Neurotech Pharmaceuticals, INC. | $412.12 | 2025 | |
| Astellas Pharma US INC | $278.05 | 2023-2025 | Izervay |
| Abbvie INC. | $226.27 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $205.61 | 2025 | |
| Genentech, INC. | $150.31 | 2022 | |
| Biotissue Holdings INC. | $147.67 | 2023 | |
| Alimera Sciences, INC. | $142.56 | 2022 | |
| Allergan, INC. | $128.43 | 2021 | |
| Bausch & Lomb Americas INC. | $123.10 | 2024 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Dompe US, INC. | $120.90 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $95.24 | 2023 | Tyrvaya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $87.91 | 2023 | Eva, Combined Machine, Tissueblue |
| Ani Pharmaceuticals, INC. | $28.88 | 2025 | Iluvien |
| Aerie Pharmaceuticals, INC. | $24.07 | 2019 | |
| Eyepoint US, INC. | $20.42 | 2023 | |
| Notal Vision, INC. | $17.50 | 2024 | Foresee Home |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Mathai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.